AbbVie (ABBV) is down -12.2%, or -$24.41 to $175.09. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ABBV: AbbVie falls -11.1% Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials AbbVie price target raised to $221 from $212 at Guggenheim AbbVie price target raised to $180 from $175 at Deutsche Bank Disclaimer & DisclosureReport an Issue
